FDA Investigates Malignancy Risk Linked to Zolgensma Gene Therapy - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Investigates Malignancy Risk Linked to Zolgensma Gene Therapy

Vector DNA integration was identified near or within the GLI1 oncogene in tumors from two treated patients

  • November 11, 2026

  • 3 min

Share

Original Source(s)

FDA Investigates Malignancy Risk Linked to Zolgensma Gene Therapy

  • November 11, 2026

Related Content

Cancer Treatment During Pregnancy and Maternal and Infant Outcomes: A Descriptive Cohort Study Using a Japanese Claims Database

Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

Predictors of Delayed and Omitted Postoperative Radiotherapy After Laryngectomy for pT4 Laryngeal Cancer